Why is ascites always treated with a combination of furosemide and spironolactone? Why is the AST usually higher than ALT in alcoholic hepatitis? The Why? Series aims to answer your burning questions about the "dogma" of liver disease, using a combination of basic physiology, scientific evidence, and clinical experiential knowledge.
Acute kidney injury (AKI) occurs in approximately 20 % of hospitalized patients with cirrhosis and is associated with increased mortality. The most common causes of AKI…
One of the most important predictors of liver related morbidity and mortality is stage of liver fibrosis. This makes identifying and quantifying the degree of…
We use several calculations to guide our management of Alcohol-Associated Hepatitis (AAH), formally known has Alcoholic Hepatitis. Have you ever wondered why? Let’s start with…
Preventative care in patients with liver disease is essential and complicated; when the liver goes down, it takes other organs down with it. In addition…
In this series, we will talk about the natural history of variceal bleeding, current standard of care, patients defined as high risk for treatment failure,…
You may have noticed that we often start antibiotics for patients with cirrhosis to prevent spontaneous bacterial peritonitis (SBP). Have you ever wondered why?
Lactulose and Rifaximin (Xifaxan) are standards of care for the prevention of overt hepatic encephalopathy in patients with cirrhosis. Have you ever wondered why? Join…
In a follow-up to an outstanding overview of NSBB therapy in liver disease, Part 2 of this series by Anahita Rabiee presents evidence in support of earlier use of NSBBs in cirrhosis. Read on!
In the first post from new LFN author Anahita Rabiee, we are gifted an authoritative review on the Whys and Hows of beta-blockade in decompensated cirrhosis! You definitely want to read this one!
In a very special installment of the Why Series, our adult and pediatric teams join forces to answer the question of how living donor liver transplantation came about in the United States. Read on!
Do you have suggestions for topics within this series? Are you a fellow interested in contributing? Please feel free to reach out via Twitter to the fellow lead or to Liver Fellow Network directly. You can also e-mail us at liverfellownetwork@gmail.com.